Management of heterogeneous tumor response patterns to immunotherapy in patients with metastatic melanoma.
Journal
Melanoma research
ISSN: 1473-5636
Titre abrégé: Melanoma Res
Pays: England
ID NLM: 9109623
Informations de publication
Date de publication:
01 02 2022
01 02 2022
Historique:
pubmed:
3
11
2021
medline:
24
3
2022
entrez:
2
11
2021
Statut:
ppublish
Résumé
Immunotherapy has revolutionized the treatment of metastatic melanoma. Response to therapy can be complex to evaluate, as Response Evaluation Criteria in Solid Tumor (RECIST) does not capture heterogeneous responses. In this retrospective single-institution analysis, we describe the management, clinicopathological characteristics, RECIST and disease course of metastatic melanoma patients with a heterogeneous response to first-line anti-CLTA-4 and/or anti-PD-1 between September 2011 and September 2020. In 196 patients, 37 had a heterogeneous response to immunotherapy (19%). Distinct identified responses included a mixed response (MR) (15%), pseudoprogressive disease (PP) (3%), and a sarcoid-like reaction (2%). Patients with a MR and possibly no response to therapy (MR-NR) had a higher median lactic acid dehydrogenase (LDH) (P = 0.01), were more often male (P = 0.04), had more involved disease sites (P = 0.01), and had brain metastasis more frequently (P = 0.02). MR patients with later response to therapy (MR-R) and PP patients had a longer overall survival of 1.7 [95% confidence interval (CI), 1.1-2.7] and 1.6 years (95% CI, 1.3-2.0) versus MR-NR 1.2 (0.7-1.7) (P < 0.01). In this cohort study, we identified prognostic clinical characteristics that can contribute to clinical decision-making for patients with a MR. Additionally, patients with pseudoprogression had benefited from therapy continuation, suggesting the importance of not halting therapy early in case of suspected PP. The male sex, more involved disease sites, brain metastasis and had a higher median LDH were associated with a poor survival for patients with a MR, suggesting that these clinical variables could be used to predict whether a mixed responder will possibly respond to therapy.
Identifiants
pubmed: 34725314
doi: 10.1097/CMR.0000000000000794
pii: 00008390-202202000-00006
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
45-54Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al.; KEYNOTE-006 Investigators. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015; 372:2521–2532.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373:23–34.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced Melanoma. N Engl J Med 2019; 381:1535–1546.
Ferrara R, Matos I. Atypical patterns of response and progression in the era of immunotherapy combinations. Future Oncol 2020; 16:1707–1713.
Kwak JJ, Tirumani SH, Van den Abbeele AD, Koo PJ, Jacene HA. Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events. Radiographics 2015; 35:424–437.
Pires da Silva I, Lo S, Quek C, Gonzalez M, Carlino MS, Long GV, et al.Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy. Cancer2020; 126:86–97.
Rauwerdink DJW, Molina G, Frederick DT, Sharova T, van der Hage J, Cohen S, Boland GM. Mixed response to immunotherapy in patients with metastatic Melanoma. Ann Surg Oncol 2020; 27:3488–3497.
Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R, et al. Novel patterns of response under immunotherapy. Ann Oncol 2019; 30:385–396.
Malaty S, Bastian CM, Ramirez-Cibes I, Shahlapour M, Dhillon W. Pembrolizumab-induced sarcoid-like reaction: FDG-PET scan interpretation in the era of immunotherapy. Cureus 2020; 12:e9449.
Comito F, Leslie I, Boos L, Furness A, Pickering L, Turajlic S, Larkin J. Oligoprogression after checkpoint inhibition in metastatic melanoma treated with locoregional therapy: a Single-center Retrospective Analysis. J Immunother 2020; 43:250–255.
Grimaldi S, Terroir M, Caramella C. Advances in oncological treatment: limitations of RECIST 1.1 criteria. Q J Nucl Med Mol Imaging 2018; 62:129–139.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228–247.
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et alRECIST Working Group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017; 18:e143–e152.
Grzywa TM, Paskal W, Włodarski PK. Intratumor and intertumor heterogeneity in Melanoma. Transl Oncol 2017; 10:956–975.
Lee JH, Long GV, Menzies AM, Lo S, Guminski A, Whitbourne K, et al. Association between circulating tumor DNA and pseudoprogression in patients with metastatic Melanoma treated with anti-programmed cell death 1 antibodies. JAMA Oncol 2018; 4:717–721.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649–655.
Gershenwald JE, Scolyer RA. Melanoma Staging: American Joint Committee on Cancer (AJCC) 8 th Edition and Beyond. Ann Surg Oncol 2018; 25:2105–2110.
Ramón Y Cajal S, Sesé M, Capdevila C, Aasen T, De Mattos-Arruda L, Diaz-Cano SJ, et al.Clinical implications of intratumor heterogeneity: challenges and opportunities. J Mol Med (Berl) 2020; 98:161–177.
Lin Z, Meng X, Wen J, Corral JM, Andreev D, Kachler K, et al. Intratumor heterogeneity correlates with reduced immune activity and worse survival in Melanoma Patients. Front Oncol 2020; 10:596493.
Quail DF, Joyce JA. The microenvironmental landscape of brain tumors. Cancer Cell 2017; 31:326–341.
Farber SH, Tsvankin V, Narloch JL, Kim GJ, Salama AK, Vlahovic G, et al. Embracing rejection: immunologic trends in brain metastasis. Oncoimmunology 2016; 5:e1172153.
Feldmann G, Brossart P, Zipfel M, von Lilienfeld-Toal M. Mixed response to ipilimumab in a melanoma patient with brain metastases: case report and review of the literature. Case Rep Oncol 2013; 6:229–235.
Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 2015; 33:3541–3543.
Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol 2016; 34:1510–1517.
Badami S, Upadhaya S, Velagapudi RK, Mikkilineni P, Kunwor R, Al Hadidi S, Bachuwa G. Clinical and molecular characteristics associated with survival in advanced melanoma treated with checkpoint inhibitors. J Oncol 2018; 2018:6279871.
Eton O, Legha SS, Moon TE, Buzaid AC, Papadopoulos NE, Plager C, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998; 16:1103–1111.
Manola J, Atkins M, Ibrahim J, Kirkwood J. Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol 2000; 18:3782–3793.